Item 8.01. Other Events.

On September 25, 2012, Alnylam Pharmaceuticals, Inc. (the "Company") filed a complaint in the Federal Court of Canada against Tekmira Pharmaceuticals Corporation ("Tekmira") for patent infringement arising from Tekmira's activities providing lipid nanoparticle-formulated small interfering RNA ("siRNA") molecules to a pharmaceutical collaborator, as well as Tekmira's own target research and validation activities. As described in the complaint, Tekmira has allegedly infringed the issued patent, CA Patent No. 2,359,180, related to siRNA technology.

The Company is seeking judgment that Tekmira has infringed the patent at issue, a permanent injunction enjoining the infringing activities, damages, and costs and expenses, including attorneys' fees.

---